PUBLICAÇÕES científicas

Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha

Panizo C, Rifón J, Rodríguez-Wilhelmi P, Cuesta B, Rocha E.
Hematology Department, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain

Revisão:Acta Haematologica

Data: 1/Jun/1999

Hematologia e Hemoterapia

Primary plasma cell leukemia (PCL) is a rare form of plasma cell neoplasm with a poor prognosis.

Conventional melphalan-based treatments have been most disappointing. We report the case of a 62-year-old man with a primary form of PCL treated with VAD combination achieving an objective response, and who received high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by interferon-alpha. During the remission time, lasting for 3 years, an infiltration by large granular lymphocytes (LGL) was noted in peripheral blood. However, when the number of LGL declined, a bone marrow relapse was observed.

The treatment for PCL and the possible role of these LGL on tumor cell control after autologous PBSC transplantation are discussed.

CITAÇÃO DO ARTIGO Acta Haematol. 1999;101(4):193-6

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra